Warfarin Versus Aspirin Recurrent Stroke Study

NCT ID: NCT00027066

Last Updated: 2011-06-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2206 participants

Study Classification

INTERVENTIONAL

Study Start Date

1993-06-30

Study Completion Date

2001-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to compare aspirin to warfarin for the prevention of recurrent stroke.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study compared aspirin to warfarin to determine optimal therapy for the prevention of recurrent stroke. Both drugs slow clotting of the blood. Blood clots are involved in the final stages of the most common type of stroke due to blockage of the vessels that supply oxygen-rich blood to the brain. Aspirin affects the blood platelets, while warfarin inhibits circulating clotting proteins in the blood. Numerous previous studies have proven that use of aspirin reduces recurrent stroke by about 25 percent. Part of the controversy about aspirin versus warfarin for stroke prevention has been the thinking among clinicians that warfarin may be a better blood thinner than aspirin to prevent almost all forms of stroke, but that it has greater side effects, increased risk of hemorrhage, and higher costs due to the need for blood tests to monitor the treatment effect for patients.

To make the aspirin and warfarin arms of the study as unbiased as possible, the investigators matched both groups of patients for primary stroke severity, age, gender, education, and race/ethnicity. The two groups were also matched for stroke risk factors, including hypertension, diabetes, cardiac disease, smoking, alcohol consumption, and physical activity. The investigators used an aspirin dose of 325 mg/day and a warfarin dose specifically tailored to each individual patient.

This study found that aspirin works as well as warfarin in helping to prevent recurrent strokes in most patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Warfarin and Aspirin Placebo

One 2 mg scored tablet daily of Warfarin and one 325 mg tablet daily of aspirin placebo.

Group Type ACTIVE_COMPARATOR

Active Warfarin

Intervention Type DRUG

2mg scored tablet daily

Aspirin placebo

Intervention Type DRUG

325mg aspirin placebo pill

Active Aspirin and Warfarin Placebo

One 325 mg tablet daily of aspirin and one 2 mg scored tablet daily of Warfarin placebo.

Group Type ACTIVE_COMPARATOR

Active Aspirin

Intervention Type DRUG

325mg tablet daily

Warfarin placebo

Intervention Type DRUG

2mg scored placebo tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active Aspirin

325mg tablet daily

Intervention Type DRUG

Active Warfarin

2mg scored tablet daily

Intervention Type DRUG

Aspirin placebo

325mg aspirin placebo pill

Intervention Type DRUG

Warfarin placebo

2mg scored placebo tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acceptable candidates for warfarin therapy
* Had an ischemic stroke within the previous 30 days
* Had scores of 3 or more on the Glasgow Outcome Scale

Exclusion:

* Base-line INR above the normal range (more than 1.4)
* History of stroke due to a procedure or that was attributed to high-grade carotid stenosis for which surgery was planned
* History of stroke associated with an inferred cardioembolic source
Minimum Eligible Age

30 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

Columbia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Columbia University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

J. P. Mohr, M.D.

Role: PRINCIPAL_INVESTIGATOR

Columbia University Health Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Columbia University Health Sciences

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01NS028371

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01NS028371

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.